Fulcrum Therapeutics, Inc. (FULC) Stock Price & Analysis
Fulcrum Therapeutics, Inc. (FULC) closed at USD 3.68 on Thursday, October 22, 2026, down 0.54% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 3.7; the Oct 22, 2026 session ranged USD 3.67–3.74 on volume of 2,309,019 shares. Market capitalization is $281.09M, with a 52-week range of USD 2.83–15.74 (NGM). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/FULC.md
Key facts (FULC)
- Analysts: Hold (mean 3.40 on a 1–5 scale) (5 analysts), mean target USD 3.67 (range 3–4).
- Total return with dividends: 1Y -58.9% vs S&P 500 +14.9%; 5Y -85.1% vs S&P 500 +80.3%.
- Next earnings: 2026-10-29, EPS estimate USD -0.11, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (FULC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $19.2M | $6.3M | $2.8M | $80.0M | $0K | — |
| Operating income | -$81.1M | -$113M | -$111M | -$21.9M | -$84.8M | -$96.0M |
| Net income | -$80.8M | -$110M | -$97.3M | -$9.7M | -$74.9M | -$85.0M |
| EPS (diluted) | -$2.29 | -$2.44 | -$1.59 | -$0.16 | -$1.18 | — |
| Free cash flow | -$80.2M | -$99.0M | -$91.5M | -$2.5M | -$60.4M | -$66.1M |
| Operating margin | -423.0% | -1774.9% | -3945.2% | -27.4% | — | — |
| Net margin | -421.9% | -1732.4% | -3470.1% | -12.2% | — | — |
| Revenue growth | +117.2% | -66.9% | -55.8% | +2752.0% | -100.0% | — |
| Cash + short-term investments | — | $35.1M | $25.6M | $58.2M | $198M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (FULC)
P/B 0.9x · FCF yield -23.53% · Earnings yield -30.24%
Analysts (FULC)
Consensus Hold (mean 3.40 on a 1–5 scale), 5 analysts; mean target USD 3.67 (low 3, high 4).
Total return (dividends reinvested) (FULC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -58.9% | -85.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -59.0% | -31.6% |
| Volatility (annualized) | 103.3% | 105.8% |
| Max drawdown | -78.5% (Dec 2025→Jun 2026) | -90.4% (Oct 2021→Apr 2023) |
Companies that name FULC in their SEC reports
| Relationship to FULC | Company | Filing | Sentence |
|---|---|---|---|
| partner | Camp4 Therapeutics Corp (CAMP) | 10-K Mar 5, 2026 | “In July 2023, we entered into a license agreement (the "Fulcrum Agreement") with Fulcrum.” |
FULC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.11 | $-0.18 | -40.1% | $0 | 2 |
| Next quarter (ends Dec 2026) | $-0.07 | $-0.17 | -60.0% | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-0.66 | $-0.82 | -20.2% | $0 | 3 |
| Next fiscal year (ends Dec 2027) | $-0.55 | $-0.66 | -16.8% | $0 | 6 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 3.68 |
|---|---|
| Change | ▼ 0.54% (down) |
| Previous Close | USD 3.7 |
| Open | USD 3.71 |
| Day Range | USD 3.67 – 3.74 |
| 52-Week Range | USD 2.83 – 15.74 |
| Volume | 2,309,019 shares |
| Market Cap | $281.09M |
| Exchange | NGM |
Technical Analysis (FULC)
Nexqual's technical model rates FULC "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.7 (neutral) |
| vs SMA50 | Below (USD 3.77) |
| MACD | -0.02 (negative) |
Analyst Ratings (FULC)
Wall Street analysts rate FULC "Hold" based on 5 analysts, with a mean price target of USD 3.67 (range USD 3–4), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 3.67 |
| High Target | USD 4 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 0 / 4 / 1 |
Earnings (FULC)
| Next Earnings Date | 2026-10-29 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.22 vs est -0.22 ▲ beat |
| 2026-03-31 | USD -0.25 vs est -0.3 ▲ beat |
| 2025-12-31 | USD -0.31 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.31 vs est -0.29 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (FULC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -32.38% |
| Debt / Equity | 0.02 |
| Current Ratio | 31.35 |
| Total Cash | $318.84M |
| Total Debt | $5.28M |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (FULC)
Nexqual rates Fulcrum Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $319M cash vs $5M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$60M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -32%, ROA -19.6% |
Ownership (FULC)
| Insider Ownership | +3.35% |
|---|---|
| Institutional Ownership | +102.18% |
| Shares Outstanding | 76.38M |
| Float | 63.49M |
| Short % of Float | +9.41% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (FULC)
Fulcrum Therapeutics, Inc. is led by Alexander C. Sapir, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| CEO, President & Director | Alexander C. Sapir |
|---|---|
| CFO, Treasurer & Principal Accounting Officer | Alan A. Musso C.M.A. |
| Senior Vice President of Early Development | Iain Fraser DPHIL |
| Head of Program Strategy & Vice President | Bobby Riehle |
Major Backers & Investors (FULC)
Notable institutional backers of Fulcrum Therapeutics, Inc. include EcoR1 Capital, LLC, Tang Capital Management, LLC, Nantahala Capital Management, LLC, according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| EcoR1 Capital, LLC | 8.58% |
| Tang Capital Management, LLC | 8.55% |
| Nantahala Capital Management, LLC | 7.18% |
| Montanova Capital LLC | 4.82% |
| Shaw D.E. & Co., Inc. | 3.99% |
| Citadel | 3.54% |
| Jane Street Group, LLC | 2.91% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.57% |
| Vanguard Group | 3.54% |
| State Street | 2.67% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt